DS
ESPR

DRW Securities’s Esperion Therapeutics ESPR Stock Holding History

DRW Securities’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Buy
+33,285
New +$93.1K ﹤0.01% 866
2018
Q2 		– Sell
-5,000
Closed -$362K – 121
2018
Q1 		$362K Buy
+5,000
New +$367K 0.02% 93

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

DRW Securities's ESPR Position: Q2 2026 in Review

DRW Securities opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 33,285 shares worth $105K. The stake represents ﹤0.01% of the portfolio and ranks #866 among its holdings. This is a return to the name: DRW Securities previously reported a position in ESPR as recently as Q1 2018.

DRW Securities first reported a position in ESPR in Q1 2018 and has held it in 2 quarters since. The position peaked at $362K in Q1 2018. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • DRW Securities held 33,285 shares of Esperion Therapeutics worth $105K as of Q2 2026.
  • Esperion Therapeutics was a new DRW Securities position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of DRW Securities's portfolio in Q2 2026, its #866 holding.
  • DRW Securities first reported a position in Esperion Therapeutics in Q1 2018 and has held it in 2 quarters since.
  • DRW Securities's Esperion Therapeutics position peaked at $362K in Q1 2018.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.